NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications

Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee NurExone Biologic welcomes Prof. Teodoro Forcht Dagi, a renowned neurosurgeon and life science venture capitalist, to its Scientific Advisory Board.